The Role of Chronic Liver Diseases in the Emergence and Recurrence of Hepatocellular Carcinoma: An Omics Perspective

Frontiers in Medicine

article

Sofia Zanotti¹  Gina F. Boot²  Mairene Coto-Llerena²  John Gallon²  Gabriel F. Hess⁴  Savas D. Soysal⁴  Otto Kollmar⁴  Charlotte K. Y. Ng⁵  Salvatore Piscuoglio² 

[1] Anatomic Pathology Unit, IRCCS Humanitas University Research Hospital;Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel;Institute of Medical Genetics and Pathology, University Hospital Basel;Clarunis, University Center for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel;Department for BioMedical Research, University of Bern;Swiss Institute of Bioinformatics;Bern Center for Precision Medicine

关键词: hepatocellular carcinoma;    chronic liver disease;    genomics;    epigenetics;    transcriptomics;    proteomics;    metabolomics;   

DOI  :  10.3389/fmed.2022.888850

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Hepatocellular carcinoma (HCC) typically develops from a background of cirrhosis resulting from chronic inflammation. This inflammation is frequently associated with chronic liver diseases (CLD). The advent of next generation sequencing has enabled extensive analyses of molecular aberrations in HCC. However, less attention has been directed to the chronically inflamed background of the liver, prior to HCC emergence and during recurrence following surgery. Hepatocytes within chronically inflamed liver tissues present highly activated inflammatory signaling pathways and accumulation of a complex mutational landscape. In this altered environment, cells may transform in a stepwise manner toward tumorigenesis. Similarly, the chronically inflamed environment which persists after resection may impact the timing of HCC recurrence. Advances in research are allowing an extensive epigenomic, transcriptomic and proteomic characterization of CLD which define the emergence of HCC or its recurrence. The amount of data generated will enable the understanding of oncogenic mechanisms in HCC from the CLD perspective and provide the possibility to identify robust biomarkers or novel therapeutic targets for the treatment of primary and recurrent HCC. Importantly, biomarkers defined by the analysis of CLD tissue may permit the early detection or prevention of HCC emergence and recurrence. In this review, we compile the current omics based evidence of the contribution of CLD tissues to the emergence and recurrence of HCC.

【 授权许可】

CC BY